CN109475620A - 抗原特异性t细胞的生产 - Google Patents

抗原特异性t细胞的生产 Download PDF

Info

Publication number
CN109475620A
CN109475620A CN201780030022.4A CN201780030022A CN109475620A CN 109475620 A CN109475620 A CN 109475620A CN 201780030022 A CN201780030022 A CN 201780030022A CN 109475620 A CN109475620 A CN 109475620A
Authority
CN
China
Prior art keywords
cell
amplification
antigen
cells
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780030022.4A
Other languages
English (en)
Chinese (zh)
Inventor
马赛厄斯·欧克
何塞·路易斯·桑托斯
金素贞
乔纳森·施内克
阿莉莎·科斯米德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nike Samuel Co Ltd
Johns Hopkins University
Original Assignee
Nike Samuel Co Ltd
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nike Samuel Co Ltd, Johns Hopkins University filed Critical Nike Samuel Co Ltd
Publication of CN109475620A publication Critical patent/CN109475620A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
CN201780030022.4A 2016-03-16 2017-03-16 抗原特异性t细胞的生产 Pending CN109475620A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309234P 2016-03-16 2016-03-16
US62/309,234 2016-03-16
PCT/US2017/022663 WO2017161092A1 (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells

Publications (1)

Publication Number Publication Date
CN109475620A true CN109475620A (zh) 2019-03-15

Family

ID=59850933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780030022.4A Pending CN109475620A (zh) 2016-03-16 2017-03-16 抗原特异性t细胞的生产

Country Status (11)

Country Link
US (2) US20200291381A1 (https=)
EP (1) EP3445399A4 (https=)
JP (1) JP7016098B2 (https=)
KR (1) KR102470979B1 (https=)
CN (1) CN109475620A (https=)
AU (1) AU2017233035B2 (https=)
CA (1) CA3017615A1 (https=)
IL (1) IL261710A (https=)
RU (2) RU2021107053A (https=)
SG (2) SG10202008210XA (https=)
WO (1) WO2017161092A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
BR112020005552A2 (pt) * 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
EP3691662A4 (en) * 2017-10-06 2021-05-12 The University of Chicago SCREENING OF T LYMPHOCYTE FOR CANCER SPECIFIC ANTIGENS
JP7580754B2 (ja) * 2018-06-20 2024-11-12 ダンマークス テクニスク ユニバーシテット 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド
WO2020061256A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
SG11202104611YA (en) 2018-11-08 2021-06-29 Neximmune Inc T cell compositions with improved phenotypic properties
US12600755B2 (en) 2020-02-27 2026-04-14 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy
WO2021262846A1 (en) * 2020-06-26 2021-12-30 The Johns Hopkins University Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
US20240066062A1 (en) * 2020-12-11 2024-02-29 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2022194742A1 (en) * 2021-03-17 2022-09-22 Miltenyi Biotec B.V. & Co. KG Artificial target for the antigen-specific activation and expansion of car t cells
US20250032617A1 (en) * 2021-10-08 2025-01-30 Baylor College Of Medicine Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers
WO2023144275A1 (en) * 2022-01-28 2023-08-03 Katholieke Universiteit Leuven Actuation of organoids by magnetic nanoparticles
DE102022132082B4 (de) * 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977095B2 (en) * 2003-05-08 2011-07-12 Life Technologies Corporation Generation and isolation of antigen-specific T cells
CN102168066A (zh) * 2011-01-31 2011-08-31 浙江大学 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法
JP2014098035A (ja) * 2008-05-02 2014-05-29 Immunovative Therapies Ltd ワクチン組成物および方法
WO2015051247A1 (en) * 2013-10-03 2015-04-09 University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
WO2015153788A1 (en) * 2014-04-01 2015-10-08 Sequenta, Llc Determining antigen-specific t-cells and b-cells
KR20150141962A (ko) * 2013-03-14 2015-12-21 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2311920C2 (ru) * 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
JP6482461B2 (ja) * 2012-07-13 2019-03-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 投与に関する形質導入ｔ細胞の適合性の評価方法
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977095B2 (en) * 2003-05-08 2011-07-12 Life Technologies Corporation Generation and isolation of antigen-specific T cells
JP2014098035A (ja) * 2008-05-02 2014-05-29 Immunovative Therapies Ltd ワクチン組成物および方法
CN102168066A (zh) * 2011-01-31 2011-08-31 浙江大学 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法
KR20150141962A (ko) * 2013-03-14 2015-12-21 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US20160051698A1 (en) * 2013-03-14 2016-02-25 The Johns Hopkins University Nanoscale Artificial Antigen Presenting Cells
WO2015051247A1 (en) * 2013-10-03 2015-04-09 University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
WO2015153788A1 (en) * 2014-04-01 2015-10-08 Sequenta, Llc Determining antigen-specific t-cells and b-cells

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A JOHN BARRETT等: "Relapse after allogeneic stem cell transplantation", 《EXPERT REVIEW OF HEMATOLOGY》 *
G WEBER等: "WT1 peptide-specific T cells generated from peripheral blood of healthy donors:possible implications for adoptive immunotherapy after allogeneic stem cell transplantation", 《IMMUNOLOGY》 *
HAVEN R GARBER等: "Adoptive T-cell therapy for Leukemia", 《MOLECULAR AND CELLULAR THERAPIES》 *
JOHN W. HICKEY等: "Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation", 《NANO LETTERS》 *
JUN HUANG等: "Detection, phenotyping, and quantification of antigen-specific T cells using a peptide-MHC dodecamer", 《PNAS》 *
KARIN SCHILBACH等: "Cytotoxic minor histocompatibility antigen HA-1–specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction", 《BLOOD》 *
KARLO PERICA等: "Enrichment and Expansion with Nano-Artificial Antigen Presenting Cells for Adoptive Immunotherapy", 《ACS NANO》 *
KARLO PERICA等: "Magnetic Field-Induced T Cell Receptor clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity", 《ACS NANO》 *
KARLO PERICA等: "Nanoscale artificial antigen presenting cells for T cell immunotherapy", 《BIOLOGY AND MEDICINE》 *
XIAO-LING LU等: "Induction of the Epstein‐Barr Virus Latent Membrane Protein 2 Antigen‐specific Cytotoxic T Lymphocytes Using Human Leukocyte Antigen Tetramer‐based Artificial Antigen‐presenting Cells", 《ACTA BIOCHIMICA ET BIOPHYSICA SINICA》 *
YEN-LING CHIU等: "HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL", 《JOURNAL OF VISUALIZED EXPERIMENTS》 *
陈彦: "异体反应性NK细胞诱导供者特异性耐受的作用机理初探", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》 *

Also Published As

Publication number Publication date
AU2017233035A1 (en) 2018-11-01
EP3445399A4 (en) 2019-10-30
US20200291381A1 (en) 2020-09-17
AU2017233035B2 (en) 2021-08-05
KR20190026645A (ko) 2019-03-13
RU2018136203A3 (https=) 2020-06-22
SG10202008210XA (en) 2020-10-29
RU2018136203A (ru) 2020-04-16
CA3017615A1 (en) 2017-09-21
SG11201807940XA (en) 2018-10-30
KR102470979B1 (ko) 2022-11-24
EP3445399A1 (en) 2019-02-27
IL261710A (en) 2018-10-31
JP7016098B2 (ja) 2022-02-21
WO2017161092A1 (en) 2017-09-21
US20230332131A1 (en) 2023-10-19
JP2019513412A (ja) 2019-05-30
RU2745319C2 (ru) 2021-03-23
RU2021107053A (ru) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7204719B2 (ja) 抗原特異的ｔ細胞を同定、濃縮、及び／または増殖させるための試薬及び方法
CN109475620A (zh) 抗原特异性t细胞的生产
Zhang et al. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
US20230399613A1 (en) Cell compositions comprising antigen-specific t cells for adoptive therapy
JP2022536089A (ja) 直接選別によるｔ細胞の製造方法およびその組成物
CN118903396A (zh) 具有改进的表型特性的t细胞组合物
US12338460B2 (en) Method for generating T cell lineage populations from stem/progenitor cells
US20230243825A1 (en) Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
WO2026035444A1 (en) Methods for identifying functional neoantigens and their use in cancer immunotherapy
CN121219583A (zh) 预测t细胞的治疗功效的标志物
HK1242367A1 (en) Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315